Modeling Retinal Ganglion Cell Degeneration from Longitudinal Intraocular Pressure Trajectories

Verdict. We address this problem by formulating retinal ganglion cell (RGC) degeneration in experimental glaucoma as a latent time-to-event process driven by longitudinal intraocular pressure (IOP) exposure. It intersects mitochondrial stress/dysfunction themes (disease context; neurodegeneration).

What the authors report

Many experimental studies collect longitudinal physiological measurements while assessing irreversible biological outcomes only at a terminal endpoint, leaving the timing of disease progression unobserved. This disconnect between continuously measured covariates and latent biological events limits quantitative analysis of how physiological stress drives tissue degeneration.

Key results stated in the abstract include the following. We address this problem by formulating retinal ganglion cell (RGC) degeneration in experimental glaucoma as a latent time-to-event process driven by longitudinal intraocular pressure (IOP) exposure. Using monthly IOP measurements and terminal RGC counts from the DBA/2J mouse model of glaucoma, we develop both Cox proportional hazards models and a time-dependent extension based on the Andersen-Gill counting-process formulation, allowing progression risk to depend on both contemporaneous IOP and cumulative pressure burden. We further reconstruct model-implied survival curves from the fitted hazard functions, providing a continuous-time representation of latent disease progression under observed and hypothetical IOP trajectories.

Why it matters for mitochondrial biology

Within mitochondrial research, this work maps primarily to redox biology, therapeutics, computational. It is relevant to mitochondrial dysfunction discourse because the abstract invokes disease context, neurodegeneration. That does not by itself establish a validated disease mechanism; it indicates thematic proximity. Because a therapeutic or interventional angle is present, the piece is of interest for mitochondrial-targeted drug hypothesis generation—subject to full-text validation of endpoints and safety context. Server: biorxiv. Posted 2026-08-14. Synthesis confidence is bounded by abstract completeness.

Study design (abstract-level)

Using monthly IOP measurements and terminal RGC counts from the DBA/2J mouse model of glaucoma, we develop both Cox proportional hazards models and a time-dependent extension based on the Andersen-Gill counting-process formulation, allowing progression risk to depend on both contemporaneous IOP and cumulative pressure burden. We further reconstruct model-implied survival curves from the fitted hazard functions, providing a continuous-time representation of latent disease progression under observed and hypothetical IOP trajectories. Across all disease thresholds and both modeling approaches, cumulative IOP burden above 19 mmHg emerged as the dominant predictor of RGC degeneration, whereas peak and contemporaneous IOP contributed little additional predictive information once sustained exposure was taken into account.

Principal findings

1. We address this problem by formulating retinal ganglion cell (RGC) degeneration in experimental glaucoma as a latent time-to-event process driven by longitudinal intraocular pressure (IOP) exposure.
2. Using monthly IOP measurements and terminal RGC counts from the DBA/2J mouse model of glaucoma, we develop both Cox proportional hazards models and a time-dependent extension based on the Andersen-Gill counting-process formulation, allowing progression risk to depend on both contemporaneous IOP and cumulative pressure burden.
3. We further reconstruct model-implied survival curves from the fitted hazard functions, providing a continuous-time representation of latent disease progression under observed and hypothetical IOP trajectories.
4. HDAP2, a mitochondria-targeted neuroprotective peptide, significantly reduced progression hazard after adjustment for longitudinal IOP exposure, supporting a pressure independent neuroprotective mechanism.
5. By linking exposure histories to model-implied survival trajectories, it enables trajectory-based risk assessment, prediction under hypothetical IOP trajectories, and quantitative evaluation of therapeutic interventions in experimental systems where biological outcomes are observed only at terminal endpoints.

Limitations of this brief

• This Mitos brief is an abstract-level synthesis of a preprint; it is not peer review and not a substitute for reading the full paper.
• Preprint status: findings may change with revision or journal review.
• Effect sizes, n numbers, statistics, and full experimental controls are typically incomplete at abstract resolution.
• Comparator/control language is weak or absent in the abstract, limiting causal inference from this brief alone.
• Evidence appears non-human or in vitro from the abstract; translational claims require independent scrutiny.
• Primary source: biorxiv DOI 10.64898/2026.08.09.743809 (posted 2026-08-14).

Open scientific questions

• Which specific experimental panels in the full paper establish the strongest causal claim, and how robust are the controls?
• What dose, timing, and off-target profile would be required to take the intervention seriously as a therapeutic hypothesis?
• How do these findings sit relative to prior literature on the same pathway—replication, contradiction, or incremental extension?

Bottom line

For mitochondrial biologists focused on redox biology, therapeutics, computational, this preprint is worth full-text review if the topic matches your program. Abstract-level takeaway: We address this problem by formulating retinal ganglion cell (RGC) degeneration in experimental glaucoma as a latent time-to-event process driven by longitudinal intraocular pressure (IOP) exposure. Confirm methods, effect sizes, and controls in the full PDF before citing the result as established.

Bibliographic record

Abstract-based editorial synthesis by Mitos. Not peer review.